KDE40104
Colorimetric
Plasma, Serum
Quantitative
78.125 - 5,000 ng/mL
33.12 ng/mL
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
LY3502970, OWL 833, OWL833, OWL-833
Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes., PMID:40481478
Current Insights, Advantages and Challenges of Small Molecule Glucagon-like Peptide 1 Receptor Agonists: A Scoping Review., PMID:40191699
[Glucagon-like peptide-1 receptor agonists: a new pharmacological treatment option for psychiatric illnesses?]., PMID:40042613
Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials., PMID:39980735
Emerging pharmacotherapies for obesity: A systematic review., PMID:39952695
Quantitative Comparison of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Adults: A Systematic Review and Model-Based Meta-Analysis., PMID:39911047
Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis., PMID:39910752
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron., PMID:39693407
Oral GLP-1 Receptor Agonists for Weight Loss., PMID:39688941
Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article., PMID:39676791
Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials., PMID:39420937
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials., PMID:39305981
Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now?, PMID:38753454
Sex, race, and BMI in clinical trials of medications for obesity over the past three decades: a systematic review., PMID:38723646
Advancements in the management of obesity: a review of current evidence and emerging therapies., PMID:38685693
Gut hormones and appetite regulation., PMID:38511400
Orforglipron, a novel non-peptide oral daily glucagon-like peptide-1 receptor agonist as an anti-obesity medicine: A systematic review and meta-analysis., PMID:38414573
Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist., PMID:38402332
Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity., PMID:38275036
Efficacy and safety of GLP-1RAs for people with obesity: A systematic review based on RCT and Bayesian network meta-analysis., PMID:38242040
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply., PMID:38091543
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity., PMID:38091542
GLP-1 Receptor Agonist Orforglipron for Adults with Obesity., PMID:38091541
Can small molecule GLP-1 agonists be the next first-line drugs in type-2 diabetes mellitus?, PMID:38048046
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes., PMID:37997518
Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials., PMID:37852529
In obesity or overweight without diabetes, orforglipron increased weight loss at 26 wk., PMID:37782925
Breaking the mold: revolutionary new obesity drugs set to transform treatment landscape?, PMID:37581246
Beyond Ozempic: brand-new obesity drugs will be cheaper and more effective., PMID:37369789
Non-peptide, once-per-day oral orforglipron to compete with established peptide-based, injectable GLP-1 receptor agonists., PMID:37369233
Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study., PMID:37369232
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity., PMID:37351564
Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon., PMID:37349257
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants., PMID:37344954
Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes., PMID:37264711
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
